Cochrane · systematic review · CD007474
Risperidone dose for schizophrenia
Li, C, Xia, J, Wang, J · Cochrane Database of Systematic Reviews · 2009 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
52
current version
GRADE rated
52
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 51 · 98.1%High 1 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
ULTRA LOW DOSE (<2 mg/day) versus ANY DOSE ‐ short term for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: Any reason ‐ when compared with standard‐low dose (greater than or equal to 4‐<6 mg/day) ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term | RR 1.3 [0.93, 1.83] | 2 studies · 461 participants | Moderate Downgraded: risk of bias |
Leaving the study early: Any reason ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term | RR 1.04 [0.76, 1.43] | 1 study · 459 participants | Moderate Downgraded: risk of bias |
Leaving the study early: Any reason ‐ when compared with high dose (greater than or equal to 10 mg) ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term | RR 0.94 [0.72, 1.23] | 1 study · 679 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ as measured by PANSS ‐ when compared with low dose (greater than or equal to 2‐<4 mg) ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term | RR 0.86 [0.29, 2.54] | 1 study · 67 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ as measured by PANSS ‐ when compared with standard‐low dose (greater than or equal to 4‐<6 mg/day) ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term | RR 1.24 [0.99, 1.55] | 1 study · 456 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ as measured by PANSS ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term | RR 1.32 [1.05, 1.66] | 1 study · 459 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ as measured by PANSS ‐ when compared with high dose (greater than or equal to 10 mg/day) ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term | RR 1.12 [0.94, 1.35] | 1 study · 679 participants | Moderate Downgraded: risk of bias |
LOW DOSE (greater than or equal to 2‐<4 mg/day) versus ANY DOSE ‐ short term for schizophrenia (continued)
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: any reason ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 0.75 [0.15, 3.72] | 1 study · 5 participants | Moderate Downgraded: risk of bias |
Leaving the study early: any reason ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 3.11 [1.41, 6.84] | 2 studies · 70 participants | Moderate Downgraded: risk of bias |
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 2.33 [1.4, 3.86] | 1 study · 70 participants | Moderate |
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 1.32 [1.06, 1.64] | 2 studies · 172 participants | Moderate |
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with high dose (greater than or equal to 10 mg/day) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 1.07 [0.92, 1.25] | 2 studies · 257 participants | Moderate |
LOW DOSE (greater than or equal to 2‐<4 mg/day) versus ANY DOSE ‐ short term for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 0.44 [0.32, 0.6] | 1 study · 124 participants | Moderate Downgraded: risk of bias |
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 0.81 [0.37, 1.75] | 2 studies · 173 participants | Moderate Downgraded: risk of bias |
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term | RR 0.45 [0.24, 0.84] | 2 studies · 262 participants | Moderate Downgraded: risk of bias |
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) versus ANY DOSE ‐ short term for schizophrenia (continued)
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: Any reasons ‐ when compared with ultra low dose (<2 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 0.77 [0.55, 1.08] | 2 studies · 461 participants | Moderate |
Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 0.78 [0.58, 1.06] | 2 studies · 496 participants | Moderate Downgraded: risk of bias |
Leaving the study early: Any reasons ‐ When compared with high dose ( greater than or equal to 10 mg) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 0.74 [0.54, 1] | 1 study · 677 participants | Moderate Downgraded: risk of bias |
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 0.74 [0.34, 1.58] | 1 study · 39 participants | Moderate Downgraded: risk of bias |
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) versus ANY DOSE ‐ short term for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: No clinically important improvement ‐ PANSS ‐ when compared with ultra low dose (<2 mg) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 0.81 [0.64, 1.01] | 1 study · 456 participants | Moderate Downgraded: risk of bias |
Mental state: No clinically important improvement ‐ PANSS ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 0.94 [0.44, 2.03] | 2 studies · 206 participants | Moderate Downgraded: risk of bias |
Mental state: No clinically important improvement ‐ PANSS ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 1.06 [0.83, 1.36] | 1 study · 457 participants | Moderate Downgraded: risk of bias |
Mental state: No clinically important improvement ‐ PANSS ‐ when compared with high dose ( greater than or equal to 10 mg) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 0.9 [0.74, 1.11] | 1 study · 677 participants | Moderate Downgraded: risk of bias |
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ dystonia ‐ versus low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 7.43 [1.07, 51.54] | 1 study · 27 participants | Moderate Downgraded: risk of bias |
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 2.28 [1.67, 3.11] | 1 study · 124 participants | Moderate Downgraded: risk of bias |
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ tremor ‐ versus low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term | RR 4.18 [1.1, 15.85] | 1 study · 27 participants | Moderate Downgraded: risk of bias |
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) versus ANY DOSE ‐ short term for schizophrenia (continued)
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.6 [0.37, 0.96] | 2 studies · 459 participants | Moderate Downgraded: risk of bias |
Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.29 [0.17, 0.52] | 2 studies · 173 participants | Moderate Downgraded: risk of bias |
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 1.38 [0.81, 2.34] | 2 studies · 496 participants | Moderate Downgraded: risk of bias |
Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.75 [0.53, 1.08] | 2 studies · 941 participants | Moderate Downgraded: risk of bias |
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.54 [0.38, 0.77] | 2 studies · 172 participants | Moderate Downgraded: risk of bias |
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 1.26 [0.46, 3.46] | 1 study · 39 participants | Moderate Downgraded: risk of bias |
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.85 [0.59, 1.22] | 2 studies · 255 participants | Moderate Downgraded: risk of bias |
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) versus ANY DOSE ‐ short term for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with ultra low dose (<2 mg) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.76 [0.6, 0.95] | 1 study · 459 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.66 [0.49, 0.9] | 3 studies · 196 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.94 [0.73, 1.2] | 1 study · 457 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with high dose (greater than or equal to 10 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.81 [0.68, 0.96] | 3 studies · 941 participants | Moderate Downgraded: risk of bias |
Adverse effects: EPS: unspecified ‐ Versus low dose (greater than or equal to 2‐<4 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 1.24 [0.57, 2.69] | 2 studies · 173 participants | Moderate Downgraded: risk of bias |
Adverse effects: EPS: unspecified ‐ Versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 2.46 [0.74, 8.14] | 1 study · 39 participants | Moderate Downgraded: risk of bias |
Adverse effects: EPS: unspecified ‐ Versus high dose (greater than or equal to 10 mg) STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term | RR 0.56 [0.31, 0.99] | 2 studies · 261 participants | Moderate Downgraded: risk of bias |
HIGH DOSE (greater than or equal to 10 mg/day) versus ANY DOSE ‐ short term for schizophrenia (continued)
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 0.66 [0.45, 0.97] | 1 study · 679 participants | Moderate Downgraded: risk of bias |
Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 0.48 [0.25, 0.92] | 1 study · 70 participants | Moderate |
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 1.64 [0.96, 2.81] | 2 studies · 677 participants | Moderate Downgraded: risk of bias |
Leaving the study early: insufficient response ‐ When compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 1.28 [0.82, 1.98] | 2 studies · 748 participants | Moderate Downgraded: risk of bias |
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 0.64 [0.5, 0.82] | 2 studies · 257 participants | Moderate Downgraded: risk of bias |
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 1.18 [0.82, 1.69] | 2 studies · 255 participants | Moderate Downgraded: risk of bias |
HIGH DOSE (greater than or equal to 10 mg/day) versus ANY DOSE ‐ short term for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with ultra low dose (<2mg) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 0.89 [0.74, 1.07] | 1 study · 679 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with low dose (greater than or equal to 2‐<4mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 0.9 [0.73, 1.12] | 2 studies · 262 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 1.11 [0.9, 1.36] | 1 study · 677 participants | Moderate Downgraded: risk of bias |
Mental state: 1. No clinically important improvement ‐ PANSS ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 1.24 [1.05, 1.47] | 3 studies · 941 participants | High |
Adverse effects: EPS: unspecified ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 1.79 [1.01, 3.18] | 2 studies · 261 participants | Moderate Downgraded: risk of bias |
Adverse effects: EPS: unspecified ‐ when compared with low dose (greater than or equal to 2‐<4mg/day) HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term | RR 2.22 [1.19, 4.14] | 2 studies · 262 participants | Moderate Downgraded: risk of bias |